ArticleAdvances in integrative medicine2020
Chinese medicine diagnosis and treatment for COVID-2019: Is China ready for implementing a national guideline?
Article in Advances in integrative medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Impact of Syndrome Differentiation on Treatment Effects and side Effects of Chinese Herbal Medicine in Randomized Controlled Trials: A Meta-Epidemiological Study.Journal of evidence-based integrative medicinePooled it
- Emergency Protective Measures and Strategies of COVID-19: From Lifestyle to Traditional Chinese Medicine.Clinical complementary medicine and pharmacology · 2023Review
- Article
- Integrative health needs to engage with effective public health interventions on merit, not oppose them on them on principle.Advances in integrative medicine · 2021Article
- Barriers and facilitators to promoting evidence uptake in Chinese medicine: a qualitative study in Hong Kong.BMC complementary medicine and therapies · 2021Article
- A public survey of traditional, complementary and integrative medicine use during the COVID-19 outbreak in Hong Kong.PloS one · 2021Article
- The potential contribution of traditional, complementary and integrative treatments in acute viral respiratory tract infections: Rapid Reviews in response to the COVID-19 pandemic.Advances in integrative medicine · 2020Article
- Maslow's hammer in integrative medicine: one size will never fit all.Advances in integrative medicine · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesCOVID-19 sparked a pandemic in December 2019 and is currently posing a huge impact globally. Chinese herbal medicine is incorporated into the Chinese national guideline for COVID-19 management, emphasising the individualisation of herbal treatment guided by
methodsThrough the case study of COVID-19 guideline implementation, we compared the three approaches of developing Chinese herbal medicine, namely
results
conclusionsMultiple COVID-19 clinical trials evaluating the effectiveness and safety of Chinese herbal medicine prescribed using one of the three approaches described above are progressing. These results will demonstrate the comparative effectiveness among these approaches. Forthcoming clinical evidence from these trials should inform the updating process of the national guideline, such that its recognition and compliance may be strengthened. For longer-term development Chinese herbal medicine, serious investment for establishing high-quality clinical research infrastructure is urgently needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.